Blog
Featured post
Regulatory-grade device evidence reimagined with new precision data
By linking unique device identifier (UDI) data with minute-level Admission–Discharge–Transfer (ADT), procedure logs, and chargemaster data, Truveta delivers the full picture of when, how, and in what context devices are used—accelerating regulatory submissions, health economics and outcomes research (HEOR), safety monitoring, and more.
Truveta experts: Adoption of MRSA testing for guiding treatment decisions
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most serious infections, often leading healthcare providers to start powerful, broad-spectrum antibiotics like...
Truveta adds new precision device data
Medical device manufacturers and regulators face a persistent challenge: obtaining a complete, clinically rich view of how devices are used, how safe they are, and how they...
Celebrating 5 years of Saving Lives with Data
Today marks the 5 year anniversary of Truveta. I personally am so humbled by where we are today. As I reflect back to where we were in 2020, the world was a very different place....
Real-world analysis links Dexcom CGM use to reduced progression of chronic kidney disease
Continuous glucose monitoring (CGM) is increasingly recognized not only for its role in diabetes management but also for its potential impact on broader health outcomes. A recent...
Truveta experts: Gestational diabetes screening in real-world practice
Gestational diabetes is one of the most common complications of pregnancy, affecting roughly 5–9% of pregnancies in the United States. When diagnosed and managed early, patients...
Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
Non–small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases and remains the leading cause of cancer death worldwide. While major advances in targeted therapies...
Johns Hopkins builds research community to explore new frontiers in health using Truveta Data
At Johns Hopkins University, the Hopkins Business of Health Initiative (HBHI) has launched the HBHI–Truveta User Community, dedicated to fostering a collaborative group of...
Impact of the CVS GLP-1 formulary change: Trends in switching
In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the...
Impact of the CVS GLP-1 formulary change: Trends in prescribing
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025...